Scynexis Inc (SCYX)

$0.82 -0.03 (-2.99%)
Market Cap 34.21M
Revenue (ttm) 3.75M
Net Income (ttm) -21.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -567.73%
Debt to Equity Ratio 0.00
Volume 140,818
Avg Vol 178,882
Day's Range N/A - N/A
Shares Out 41.93M
Stochastic %K 64%
Beta 1.64
Analysts Strong Sell
Price Target $4.67

Company Profile

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, a drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 884 5485
Address:
1 Evertrust Plaza, 13th Floor, Jersey City, United States
whob007
whob007 Aug. 26 at 7:21 PM
$SCYX SCYX is going to break out to new highs and GSK is going to cave cause they will want SCY-247
1 · Reply
gifor
gifor Aug. 26 at 5:32 PM
$SCYX seems to be breaking out
1 · Reply
XZeroDelta
XZeroDelta Aug. 24 at 4:24 PM
$SCYX here is the follow-up post with a screenshot of what Copilot told me regarding the milestone payments that Scynexis would receive from Hansoh pharmaceuticals upon commercialization of ibrexafungerp (called commercially Hengmeida in China). Scynexis is not going to go bankrupt. GSK will have to honor their arrangement with Scynexis and/or offer them and us share holders something good in return. No sweat!!!
0 · Reply
XZeroDelta
XZeroDelta Aug. 24 at 4:15 PM
$SCYX As per Microsoft's Copilot, I asked it when we could expect the "Estimated Commercial Launch of Hengmeida (ibrexafungerp) in China" and here is a screenshot of what it said. Basically on or after September 2025 when can expect it to be sold which would then trigger milestone payments which Hansoh would have to pay Scynexis. I will include the screenshot asking Copilot about the milestone money that Scynexis will receive upon commercialization of ibrexafungerp in another post. Basically, this stock is already primed to go up!!!
0 · Reply
ViktorSinclair
ViktorSinclair Aug. 22 at 3:03 PM
$SCYX For the life of me I don't understand why David lets it get to this point. It does not have to be this way. He needs better advisors. BOD is a waste of time
0 · Reply
LemuelPitkin
LemuelPitkin Aug. 21 at 2:58 PM
$SCYX Grok: SCYNEXIS is actively working to transfer the BREXAFEMME New Drug Application (NDA) to GSK by the end of 2025, as part of their exclusive license agreement. This transfer is intended to enable GSK to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC. However, as of the latest available information from August 2025, the transfer process is ongoing and has not been explicitly confirmed as completed.
1 · Reply
LemuelPitkin
LemuelPitkin Aug. 20 at 6:20 PM
$SCYX SCYX was very wise to not hand over the NDA until GSK fulfilled its full contract. By not handing it over, that NDA is available to be sold to a different company. Should GSK continue to violate its obligations. The NDA is key leverage. Once you hand it over, you have to fight uphill should the other party not live up to its word. Good move, Scynexis!
2 · Reply
LemuelPitkin
LemuelPitkin Aug. 20 at 2:51 PM
$SCYX Grok: Below are the likely reasons for the extended timeline, based on available information and general principles of NDA transfers: Ongoing Dispute Over Milestone Payments: SCYNEXIS and GSK are in a disagreement regarding milestone payments tied to the Phase 3 MARIO study for Brexafemme’s potential use in invasive candidiasis. SCYNEXIS claims a $10 million payment was triggered by resuming the study and expects another $20 million in six months, but GSK disputes these obligations...
1 · Reply
pjinvestmentco
pjinvestmentco Aug. 20 at 12:13 PM
$SCYX Does anyone think your not dealing with 2 incompetent companies based on this off the Scynexis earnings report. Its has taken over 2 years to transfer the Brexafemme NDA to GSK and it won't be relaunched until sometime 2026?? Don't invest with idiots is what you take from this... "SCYNEXIS is working to transfer the BREXAFEMME NDA to GSK by the end of 2025. Once this transfer has been completed, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market"
2 · Reply
pjinvestmentco
pjinvestmentco Aug. 19 at 12:53 PM
$SCYX Maybe David needs to add AI to SCY-247 to help the stock Maxim update today (Tuesday) no SCYX
1 · Reply
Latest News on SCYX
SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:30 PM EDT - 13 days ago

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025, 8:30 AM EDT - 3 months ago

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 5 months ago

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:30 PM EST - 10 months ago

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 10, 2024, 8:00 AM EDT - 11 months ago

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

Oct 3, 2024, 8:00 AM EDT - 11 months ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

Jul 23, 2024, 7:00 AM EDT - 1 year ago

SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 4:30 PM EDT - 1 year ago

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

Apr 30, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Apr 9, 2024, 4:05 PM EDT - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Scynexis: Update Following Restructuring Of GSK Deal

Apr 2, 2024, 10:04 AM EDT - 1 year ago

Scynexis: Update Following Restructuring Of GSK Deal

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 4:01 PM EDT - 1 year ago

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Jan 29, 2024, 5:15 PM EST - 1 year ago

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 8, 2024, 4:00 AM EST - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

Jan 5, 2024, 8:30 AM EST - 1 year ago

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Jan 4, 2024, 7:00 AM EST - 1 year ago

JANUARY 8 FINAL DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

Dec 29, 2023, 4:00 AM EST - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

Dec 28, 2023, 9:00 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 22, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 21, 2023, 8:00 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 19, 2023, 5:30 AM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

Dec 18, 2023, 6:46 PM EST - 1 year ago

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 18, 2023, 6:15 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 13, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 8, 2023, 5:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 6, 2023, 7:00 AM EST - 1 year ago

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

Dec 4, 2023, 7:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Dec 1, 2023, 6:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

Nov 30, 2023, 8:30 AM EST - 1 year ago

SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 29, 2023, 7:50 PM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 22, 2023, 11:45 PM EST - 1 year ago

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 21, 2023, 7:00 AM EST - 1 year ago

IMPORTANT JANUARY DEADLINE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 19, 2023, 11:45 PM EST - 1 year ago

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

Nov 17, 2023, 11:15 AM EST - 1 year ago

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

Nov 15, 2023, 1:15 PM EST - 1 year ago

SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc.

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 5:17 PM EST - 1 year ago

SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

Oct 24, 2023, 8:00 AM EDT - 2 years ago

SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

Oct 6, 2023, 5:20 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors

whob007
whob007 Aug. 26 at 7:21 PM
$SCYX SCYX is going to break out to new highs and GSK is going to cave cause they will want SCY-247
1 · Reply
gifor
gifor Aug. 26 at 5:32 PM
$SCYX seems to be breaking out
1 · Reply
XZeroDelta
XZeroDelta Aug. 24 at 4:24 PM
$SCYX here is the follow-up post with a screenshot of what Copilot told me regarding the milestone payments that Scynexis would receive from Hansoh pharmaceuticals upon commercialization of ibrexafungerp (called commercially Hengmeida in China). Scynexis is not going to go bankrupt. GSK will have to honor their arrangement with Scynexis and/or offer them and us share holders something good in return. No sweat!!!
0 · Reply
XZeroDelta
XZeroDelta Aug. 24 at 4:15 PM
$SCYX As per Microsoft's Copilot, I asked it when we could expect the "Estimated Commercial Launch of Hengmeida (ibrexafungerp) in China" and here is a screenshot of what it said. Basically on or after September 2025 when can expect it to be sold which would then trigger milestone payments which Hansoh would have to pay Scynexis. I will include the screenshot asking Copilot about the milestone money that Scynexis will receive upon commercialization of ibrexafungerp in another post. Basically, this stock is already primed to go up!!!
0 · Reply
ViktorSinclair
ViktorSinclair Aug. 22 at 3:03 PM
$SCYX For the life of me I don't understand why David lets it get to this point. It does not have to be this way. He needs better advisors. BOD is a waste of time
0 · Reply
LemuelPitkin
LemuelPitkin Aug. 21 at 2:58 PM
$SCYX Grok: SCYNEXIS is actively working to transfer the BREXAFEMME New Drug Application (NDA) to GSK by the end of 2025, as part of their exclusive license agreement. This transfer is intended to enable GSK to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC. However, as of the latest available information from August 2025, the transfer process is ongoing and has not been explicitly confirmed as completed.
1 · Reply
LemuelPitkin
LemuelPitkin Aug. 20 at 6:20 PM
$SCYX SCYX was very wise to not hand over the NDA until GSK fulfilled its full contract. By not handing it over, that NDA is available to be sold to a different company. Should GSK continue to violate its obligations. The NDA is key leverage. Once you hand it over, you have to fight uphill should the other party not live up to its word. Good move, Scynexis!
2 · Reply
LemuelPitkin
LemuelPitkin Aug. 20 at 2:51 PM
$SCYX Grok: Below are the likely reasons for the extended timeline, based on available information and general principles of NDA transfers: Ongoing Dispute Over Milestone Payments: SCYNEXIS and GSK are in a disagreement regarding milestone payments tied to the Phase 3 MARIO study for Brexafemme’s potential use in invasive candidiasis. SCYNEXIS claims a $10 million payment was triggered by resuming the study and expects another $20 million in six months, but GSK disputes these obligations...
1 · Reply
pjinvestmentco
pjinvestmentco Aug. 20 at 12:13 PM
$SCYX Does anyone think your not dealing with 2 incompetent companies based on this off the Scynexis earnings report. Its has taken over 2 years to transfer the Brexafemme NDA to GSK and it won't be relaunched until sometime 2026?? Don't invest with idiots is what you take from this... "SCYNEXIS is working to transfer the BREXAFEMME NDA to GSK by the end of 2025. Once this transfer has been completed, GSK will be able to initiate regulatory interactions with the U.S. Food and Drug Administration (FDA) in 2026 to discuss the relaunch of BREXAFEMME for vulvovaginal candidiasis (VVC) and refractory vulvovaginal candidiasis (rVVC) in the U.S. market"
2 · Reply
pjinvestmentco
pjinvestmentco Aug. 19 at 12:53 PM
$SCYX Maybe David needs to add AI to SCY-247 to help the stock Maxim update today (Tuesday) no SCYX
1 · Reply
LemuelPitkin
LemuelPitkin Aug. 18 at 10:02 PM
$SCYX Grok: "On May 29, 2025, AInvest reported that SCYNEXIS maintained a Buy rating from Maxim Group due to the resumption of the Phase 3 MARIO study and financial stability."
2 · Reply
pjinvestmentco
pjinvestmentco Aug. 18 at 12:22 PM
$SCYX Looks like Maxim dropped coverage on Scynexis the last analyst to follow the deadbeat company
0 · Reply
whob007
whob007 Aug. 15 at 5:04 PM
$SCYX MNTB Killing it last 3 days and they have a fungal drug used in compassionate cases SCYX is next
2 · Reply
whob007
whob007 Aug. 15 at 3:57 PM
$SCYX I am increasing my Price target to 6.10 and rating SCYX a strong buy right here right now
3 · Reply
pjinvestmentco
pjinvestmentco Aug. 15 at 1:44 AM
$SCYX GSK and SCYX have taken 2 years to resolve a recall for a minor manufacturing issue which initially Scynexis didn't consider an issue. Both these companies may have the most incompetent management teams and neither one is investable in my opinion.
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader Aug. 15 at 1:14 AM
$SCYX 14 months till BK
1 · Reply
HJRaph
HJRaph Aug. 15 at 12:44 AM
$SCYX
2 · Reply
pjinvestmentco
pjinvestmentco Aug. 14 at 8:27 PM
$SCYX David should immediately be demoted to Chief Scientific Officer!! Hey clown, I know you don't answer any questions but I have 50 but here is one.. Hansoh was approved in China for Brexafemme when do any of the milestone payments hit? when does Hansoh launch Brexafemme?? Does Hansoh have any product or is that on recall also??
1 · Reply
WarrenDouglasTrader
WarrenDouglasTrader Aug. 14 at 8:08 PM
$SCYX Well, this thing is done.
1 · Reply
LemuelPitkin
LemuelPitkin Aug. 14 at 7:45 PM
$SCYX
0 · Reply
LemuelPitkin
LemuelPitkin Aug. 14 at 7:42 PM
$SCYX
0 · Reply
XZeroDelta
XZeroDelta Aug. 14 at 11:35 AM
$SCYX Second Quarter 2025 Results https://ir.scynexis.com/news-events/press-releases/detail/347/scynexis-reports-second-quarter-2025-financial-resultsand
2 · Reply